Hepa - Merz

Hepa, marketed by Merz, contains the active ingredient ornithine aspartate and is supplied for intravenous administration in the European Union. It is formulated as a sterile solution intended for infusion by healthcare professionals. Ornithine aspartate is a compound that has been studied for its role in nitrogen metabolism and liver function, and Hepa is used in clinical settings where intravenous delivery is appropriate.

Hepa is administered intravenously in a hospital or clinical environment for conditions where modulation of nitrogen metabolism may be beneficial. Typical clinical contexts include: - Supportive care in patients with acute liver dysfunction - Adjunct therapy during hepatic encephalopathy management - Use in postoperative care where liver stress is anticipated - Investigation in clinical trials evaluating hepatic metabolic support - Situations requiring rapid correction of plasma amino acid levels

Side effects associated with intravenous ornithine aspartate are generally uncommon but may occur. They are categorized by frequency and severity.

Common: - Mild nausea or vomiting - Transient headache - Temporary flushing or warmth at the infusion site - Mild hypotension during infusion - Slight increase in serum ammonia levels - Mild electrolyte disturbances

Serious: - Severe allergic reaction (anaphylaxis) - Acute respiratory distress - Significant hypotension requiring intervention - Persistent elevation of liver enzymes - Renal impairment in susceptible individuals - Hemolysis or severe hemolytic anemia

When considering Hepa for intravenous use, clinicians should observe several safety measures: - Verify patient history for hypersensitivity to ornithine or aspartate compounds. - Assess liver function tests before and during therapy. - Monitor blood pressure and vital signs throughout the infusion. - Use caution in patients with renal insufficiency or electrolyte imbalances. - Adjust infusion rate if signs of hypotension or discomfort arise. - Ensure proper aseptic technique to prevent infection at the infusion site. - Document any adverse reactions promptly for pharmacovigilance.

Intravenous ornithine aspartate may interact with other medications or substances. Interactions are grouped by level of concern.

Avoid: - Concurrent use of high-dose ammonia‑producing agents (e.g., certain chemotherapy drugs). - Co‑administration with potent vasodilators that may exacerbate hypotension. - Simultaneous infusion with incompatible solutions (e.g., calcium‑containing fluids).

Use with caution: - Diuretics that affect electrolyte balance. - Medications metabolized by the liver, such as acetaminophen. - Anticoagulants, due to potential changes in plasma protein binding. - Drugs that alter renal clearance, including ACE inhibitors.